Table 1 Respiratory support requirements.

From: Tocilizumab reduces COVID-19 mortality and pathology in a dose and timing-dependent fashion: a multi-centric study

Parameter

Odds ratio at 95%

Reduction of RSR (severely-ill)

2.71 (1.37–4.85)

Reduction of RSR (moderately-ill)

2.82 (1.47–4.91)

Prevention of progression to MV

2.02 (0.51–8.0)

  1. CI confidence interval, RSR respiratory support requirements, MV mechanical ventilation.